Clinical Research Operations Core

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

NATIONAL INSTITUTES OF HEALTH NIAID

Contract Value

Not provided

Codes & Classification
Solicitation Number

75N93025R00019

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Classification Code

AN12

Additional Details
Set Aside

NONE

Place of Performance

Rockville, Maryland, UNITED STATES

SourceSAM
Documents1
The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, has issued a presolicitation notice for the Clinical Research Operations Core, under procurement identifier 75N93025R00019. This forthcoming solicitation seeks to secure comprehensive resources and services essential for the implementation of clinical research activities that directly support NIAID’s mission. The overarching goal is to enable NIAID to respond effectively to public health needs—including emergencies—and to generate high-quality data that informs regulatory and policy decisions. The scope of this procurement encompasses support for a diverse array of investigators across multiple scientific disciplines. Contractors will be expected to facilitate the acquisition of critical data necessary for investigators to pursue additional funding, establish prospective partnerships for further development or Phase I/II clinical trials, meet regulatory requirements, and advance Phase I/II clinical studies. In addition, the contract will support NIAID priority activities, such as the manufacture and characterization of reagents and products for government-sponsored clinical trials, including those under the Infectious Diseases Clinical Research Consortium (IDCRC). The contractor will also be responsible for the manufacture of critical reagents and clinical trial materials to benefit the broader scientific community, including non-government sponsored projects. A notable requirement is the implementation of a Determination of Exceptional Circumstances in accordance with 37 C.F.R. § 401.3(e), specifically for NIAID’s preclinical service contracts involving vaccine and other biologic manufacturing services for infectious diseases. Under this provision, all contractors must operate on a fee-for-service basis. Furthermore, contractors may be required to assign any intellectual property (IP) they develop related to third-party materials (“Provider Materials”), new processes, or products derived from Provider Materials. Public release of results must be delayed until both NIAID and the Provider have had the opportunity to review and file patents. While contractors may propose the use of proprietary or licensed reagents and processes, NIAID and the Provider retain the right to reject such alternatives. The procurement is classified under NAICS code 541715, which covers Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology), and is further identified by Product Service Code AN12. There is no set-aside for small businesses or other socioeconomic categories, indicating that the opportunity is open to all qualified entities. The place of performance is Rockville, Maryland, United States. The contracting entity is the National Institutes of Health (NIH), specifically NIAID, operating as a federal office. Interested parties should direct inquiries to the primary contact, Cindy Hargett ([email protected]), or the contracting officer, Ignacio Reyes ([email protected], 301-435-7574). The notice was posted on January 13, 2026, and responses are due by February 27, 2026. The opportunity remains active and is accessible via the SAM.gov portal at https://sam.gov/opp/334bc7f25be74ff1a07de1c61ea7c2c6/view. Contractors considering this opportunity should ensure they have the capacity to deliver high-quality clinical research support, including the manufacture and characterization of reagents and clinical trial materials, and are prepared to comply with the intellectual property and publication requirements outlined by NIAID. The contract’s requirements and objectives are expected to remain consistent throughout its lifecycle, focusing on supporting NIAID’s mission and the broader scientific community in advancing clinical research and public health outcomes.